Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria
- PMID: 12880188
- DOI: 10.1007/BF03325000
Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria
Abstract
Objective: There are many health risks involved with the use of weight loss products by normal weight women. The mass media may compound this problem through the promotion of weight loss products and a thin body size. This study tested women's perceptions of different weight loss product ads to determine if body dysphoria (i.e., an over concern with body size and shape in normal weight people) was associated with risk beliefs, past behaviors, and intention toward using weight loss products.
Method: Normal weight women (age range = 18-41 yr), who were classified as either high (n=45) or low (n=43) on a measure of body dysphoria, rated different weight loss products according to their perception of health risks, past behavior, and their intention to consume the products. These products were a dietary fat substitute (olestra), a prescription obesity medication (sibutramine), and an over-the-counter appetite suppressant (phenylpropanolamine).
Results: High body dysphoric women reported higher intentions to use the products as well as increased prior use of two of the three weight loss products. High body dysphoric women did not believe that these weight loss products were harmless. They recognized potential health risks associated with using such products, but nonetheless, expressed intention to use these weight loss products at a higher frequency. Also, several variables related to body image were found to effectively discriminate normal weight women at risk for abusing weight loss products.
Discussion: This study found that women who do not need to lose weight but have significant body image concerns were willing to use potentially harmful weight loss products despite the knowledge that such products might pose significant health risks. Techniques utilized by advertising regulatory agencies such as warning labels did not have a strong deterrent effect for stated intentions to use the products. Implications of these findings for public health policy issues were discussed.
Similar articles
-
A role for olestra in body weight management.Obes Rev. 2002 Feb;3(1):17-25. doi: 10.1046/j.1467-789x.2002.00050.x. Obes Rev. 2002. PMID: 12119656 Review.
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
-
Use of nonprescription weight loss products: results from a multistate survey.JAMA. 2001 Aug 22-29;286(8):930-5. doi: 10.1001/jama.286.8.930. JAMA. 2001. PMID: 11509057
-
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.JAMA. 2003 Apr 9;289(14):1805-12. doi: 10.1001/jama.289.14.1805. JAMA. 2003. PMID: 12684359 Clinical Trial.
-
The effect of ingesting olestra-based foods on feeding behavior and energy balance in humans.Crit Rev Food Sci Nutr. 2001 Jul;41(5):363-86. doi: 10.1080/20014091091850. Crit Rev Food Sci Nutr. 2001. PMID: 11497329 Review.
Cited by
-
Characteristics and behaviors of non-overweight college students who are trying to lose weight.J Prim Prev. 2013 Aug;34(4):251-60. doi: 10.1007/s10935-013-0309-0. J Prim Prev. 2013. PMID: 23712639
References
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous